Nucleoside analogues in previously treated Waldenström’s macroglobulinemia (reviewed in Merlini and Treon21 ).
| Study . | Number of Patients . | Median Number of Courses . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|
| a ≥ 50% reduction in serum IgM levels. | ||||
| Abbreviations: NA, not applicable; RR, response rate. | ||||
| Cladribine | ||||
| Dimopoulos | 46 | 2 | 43% | 12 months |
| Delannoy | 13 | 2 | 38% | NA |
| Betticher | 25 | 3 | 40% | 8 months |
| Liu | 13 | 3 | 54% | NA |
| Hellman | 13 | 4 | 38% | NA |
| Fludarabine | ||||
| Dimopoulos | 26 | 3 | 31% | NA |
| Zinzani | 12 | 6 | 41% | 10+ months |
| Leblond | 71 | 6 | 30% | 32 months |
| Dhodapkar | 64 | 4–8 | 33% | 30 months |
| Study . | Number of Patients . | Median Number of Courses . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|
| a ≥ 50% reduction in serum IgM levels. | ||||
| Abbreviations: NA, not applicable; RR, response rate. | ||||
| Cladribine | ||||
| Dimopoulos | 46 | 2 | 43% | 12 months |
| Delannoy | 13 | 2 | 38% | NA |
| Betticher | 25 | 3 | 40% | 8 months |
| Liu | 13 | 3 | 54% | NA |
| Hellman | 13 | 4 | 38% | NA |
| Fludarabine | ||||
| Dimopoulos | 26 | 3 | 31% | NA |
| Zinzani | 12 | 6 | 41% | 10+ months |
| Leblond | 71 | 6 | 30% | 32 months |
| Dhodapkar | 64 | 4–8 | 33% | 30 months |